Paradoxical activation of oncogenic signaling as a Cancer treatment strategy

Full metadata record
DC FieldValueLanguage
dc.contributor(LCC) Lab. Ciclo Celularpt_BR
dc.contributor(CeTICS) Centro de Toxinas, Resposta-imune e Sinalização Celularpt_BR
dc.contributor.authorDias, Matheus Henriquept_BR
dc.contributor.authorFriskes, Anoekpt_BR
dc.contributor.authorWang, Siyingpt_BR
dc.contributor.authorMoreira, Rosangela Aparecida Wailemannpt_BR
dc.contributor.authorArmelin, Hugo Aguirrept_BR
dc.date.accessioned2024-06-13T13:56:08Z-
dc.date.available2024-06-13T13:56:08Z-
dc.date.issued2024pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/5384-
dc.description.abstractCancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance.pt_BR
dc.description.sponsorship(ERC) European Research Councilpt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.description.sponsorship(NSFC) National Natural Science Foundation of Chinapt_BR
dc.description.sponsorshipProgram of Shanghai Academic/Technology Research Leaderpt_BR
dc.description.sponsorshipInstituto de Salud Carlos IIIpt_BR
dc.description.sponsorship(EU) European Unionpt_BR
dc.format.extent1276-1301pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofCancer Discoverypt_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_BR
dc.titleParadoxical activation of oncogenic signaling as a Cancer treatment strategypt_BR
dc.typeArticlept_BR
dc.rights.licenseCC BYpt_BR
dc.identifier.doi10.1158/2159-8290.CD-23-0216pt_BR
dc.identifier.urlhttps://doi.org/10.1158/2159-8290.CD-23-0216pt_BR
dc.contributor.externalNetherlands Cancer Institutept_BR
dc.contributor.externalShanghai Cancer Institutept_BR
dc.contributor.externalHubrecht Institutept_BR
dc.contributor.externalIdibell Institut D'investigació Biomèdica De Bellvitgept_BR
dc.contributor.external(UNIFESP) Universidade Federal de São Paulopt_BR
dc.contributor.externalUniversity of Icelandpt_BR
dc.contributor.externalEastern Hepatobiliary Surgery Hospitalpt_BR
dc.contributor.externalLixte Biotechnology Holdingspt_BR
dc.identifier.citationvolume14pt_BR
dc.identifier.citationissue7pt_BR
dc.relation.ispartofabbreviatedCancer Discovpt_BR
dc.identifier.citationabntv. 14, n. 7, p. 1276-1301, 2024pt_BR
dc.identifier.citationvancouver2024; 14(7):1276-1301pt_BR
dc.contributor.butantanMoreira, Rosangela Aparecida Wailemann|:Pós-Doc|:Pesquisador|:Programa de Pós-Doutorado|:(CeTICS) Centro de Toxinas, Resposta-imune e Sinalização Celular|:(LCC) Lab. Ciclo Celular|:(CeTICS) Centro de Toxinas, Resposta-imune e Sinalização Celularpt_BR
dc.contributor.butantanArmelin, Hugo Aguirre|:Pesquisador|:(LCC) Lab. Ciclo Celular|:(CeTICS) Centro de Toxinas, Resposta-imune e Sinalização Celularpt_BR
dc.sponsorship.butantan(ERC) European Research Council¦¦ERC-787925pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2019/10753-2pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2020/10277-3pt_BR
dc.sponsorship.butantan(NSFC) National Natural Science Foundation of China¦¦82222047pt_BR
dc.sponsorship.butantanProgram of Shanghai Academic/Technology Research Leader¦¦22XD1423100pt_BR
dc.sponsorship.butantanInstituto de Salud Carlos III¦¦FI20/00130pt_BR
dc.sponsorship.butantanInstituto de Salud Carlos III¦¦PI19- 01320pt_BR
dc.sponsorship.butantanInstituto de Salud Carlos III¦¦PI22-00548pt_BR
dc.sponsorship.butantan(EU) European Union¦¦2017SGR449pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2013/07467-1pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.fulltextSem Texto completo-
item.languageiso639-1English-
item.openairetypeArticle-
item.grantfulltextnone-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0001-9557-0804-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos

Show simple item record

This item is licensed under a Creative Commons License Creative Commons